Download PDF

Other users also viewed these articles

Do patients with axial spondyloarthritis with active disease suffer from greater disease burden and work impairment? Results from the International Map of Axial Spondyloarthritis (IMAS) Marco Garrido-Cumbrera; Denis Poddubnyy; Fernando Sommerfleck; Christine Bundy; Souzi Makri; José Correa-Fernández; Shashank Akerkar; Jo Lowe; Elie Karam; Victoria Navarro-Compán;
Reumatol Clin. 2024;20:547-54
Resources and strategies for the optimal care of patients with axial spondyloarthritis: The CREA project Cristina Fernández-Carballido; Raquel Almodóvar; Juan D. Cañete; Eduardo Collantes; Eugenio de Miguel; Jordi Gratacós; Xavier Juanola; José A. Pinto; Rubén Queiro; Pedro Zarco;
Reumatol Clin. 2023;19:82-9
One-year retention rate of ixekizumab in patients with psoriatic arthritis and axial spondyloarthritis: Real-world data from the BIOBADASER registry Clementina López-Medina; Lucía Otero-Varela; Fernando Sánchez-Alonso; Vega Jovaní; Lorena Expósito-Pérez; Sheila Melchor-Díaz; Yanira Pérez-Vera; Paula Pretel-Ruiz; Javier Manero; Antonio Mera-Varela; Lourdes Mateo; Dolores Ruiz-Montesino; José Andrés Lorenzo-Martín; Teresa Pedraz-Penalva; Isabel Castrejón;
Reumatol Clin. 2025;21: